Furthermore, there are four related literatures on the PubMed website reporting the relationship between CREB5 and tumor resistance [17, 46–48], of which only one paper preliminarily clarified the molecular mechanism of CREB5 promoting prostate cancer resistance to androgen receptor antagonists [17]. Here, AR is linked to prostate carcinoma.